MK-4464

· Merck Sharp & Dohme LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MK-4464, covering 2025-10-09 to 2025-10-09. Get the full timeline:

Most recent: Clinical Trial Update: Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) [Phase 1]

See pricing